Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease : Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial
Citation
Wilcock , G K , Gauthier , S , Frisoni , G B , Jia , J , Hardlund , J H , Moebius , H J , Bentham , P , Kook , K A , Schelter , B O , Wischik , D J , Davis , C S , Staff , R T , Vuksanovic , V , Ahearn , T , Bracoud , L , Shamsi , K , Marek , K , Seibyl , J , Riedel , G , Storey , J M D , Harrington , C R & Wischik , C M 2017 , ' Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease : Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial ' , Journal of Alzheimer's Disease , vol. 61 , no. 1 , pp. 435-457 . https://doi.org/10.3233/JAD-170560
Rights
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0). https://creativecommons.org/licenses/by/4.0/